Follow Us:
Wednesday, May 12, 2021

350 oncologists to discuss non-cancer medicines in cancer treatment at Mumbai’s Tata Memorial Hospital

Three clinical trials are now underway at the hospital for checking effects of such drugs.

By: Express News Service | Mumbai |
May 5, 2016 2:17:30 am
oncologists, Tata Memorial Hospital, mumbai, mumabi news, mumbai Tata Memorial Hospital, indian express mumbai, cancer treatment in mumbai Cancer specialists at a conference to discuss the use of metronomics in cancer treatment in Parel, Mumbai on Wednesday.

Cancer specialists from across the globe are set to meet at Mumbai’s Tata Memorial Hospital for a three-day event to discuss whether non-oncology drugs can be put to use for treating cancer or preventing its relapse. The conference, International Metronomic and Anti-Angiogenic Meeting, will start from Friday. According to Dr Shripad Banavali, Pediatric Oncology Head at the hospital, metronomic therapy consist of drugs that are primarily not used to treat cancer but have found anecdotal reports of benefits in treating the disease.

Three clinical trials are now underway at the hospital for checking effects of such drugs. One trial, that will cover 11,000 patients, deals with use of aspirin on breast cancer, while two other trials are underway for checking whether selicoxiv and metotresate can be used for esophagus and head and neck cancer treatment.

The conference will have 350 delegates from various countries who will present their paper on use of metronomics for cancer treatment.

According to Dr Sudeep Gupta, Medical Oncologist at the hospital, the use of non-cancer drugs makes treatment cheaper and more affordable for patients of lower income groups.


📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Mumbai News, download Indian Express App.

  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.